Bio-Path Holdings Employee Directory
Biotechnology ResearchTexas, United States2-10 Employees
Bio-Path Holdings is a publicly traded biotechnology company based in Bellaire, Texas, focused on developing therapeutic products using its proprietary liposomal delivery platform to distribute nucleic acid drugs via intravenous infusion. The lead candidate, BP1001 (Liposomal Grb-2), has completed the safety portion of a Phase II trial in acute myeloid leukemia in combination with frontline therapy for induction-therapy-ineligible patients, and a second Phase II safety segment for chronic myeloid leukemia is planned for the first half of 2016. A second liposomal antisense drug candidate is ready for clinical evaluation in lymphoma and solid tumors. Bio-Path's antisense DNA delivery technology, branded DNAbilize, is available for licensing and is designed to enable systemic distribution and targeting of genes beyond the liver, with no observed toxicity in patients to date. The company maintains a small employee base (2-10 people) and has engaged in governance and collaboration activities, including the formation of a scientific advisory board in 2026.